In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Nuplazid (Acadia)
- INDICATIONS: Hallucinations and delusions associated with Parkinson’s disease psychosis
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 57 hours
- FDA APPROVAL DATE: 04/29/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carbamazepine, Chlorpromazine, Clarithromycin, Disopyramide, Drugs known to prolong the QT interval, Gatifloxacin, Indinavir, Itraconazole, Ketoconazole, Moxifloxacin, Phenytoin, Procainamide, Quinidine, Rifampin, Sotalol, St John's Wort, Strong CYP3A4 inhibitors and inducers, Thioridazine, Ziprasidone - PREGNANCY: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 08/22/2024
